Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02957682 · ClinicalTrials.gov registry record · Phase 4
Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
A Phase 4 study of Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 2,176
- Enrollment target
- 20
- Study locations
NCT02957682: Completed Phase 4 study of Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals.
NCT02957682 is a Phase 4 study of Hypercholesterolemia that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 2,176 participants, above the 782-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (178% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02957682, a Phase 4 study of Hypercholesterolemia, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2,176 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.
Primary Outcome
CANTAB SWM task assessed cognitive domain of executive function. Colored boxes were shown on a screen. A token was hidden in one of the boxes (never same box twice). Instructions were to touch boxes to search for token until number of tokens found equaled number of boxes. SWM strategy index represents number of times a search began with a different box. Z-score represents standardized measure of how far an individual deviated from study cohort average at baseline. A higher Z-score reflects bette
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Praluent (Alirocumab)
Study Locations (20)
California
- Regeneron Study Site - Beverly Hills
- Regeneron Study Site - Los Gatos
- Regeneron Study Site - North Hollywood
- Regeneron Study Site - Port Hueneme
- Regeneron Study Site - Westminster
Illinois
- Regeneron Study Site - Champaign
- Regeneron Study Site - Chicago
- Regeneron Study Site - Chicago
- Regeneron Study Site - Rock Island
Alabama
- Regeneron Study Site - Auburn
- Regeneron Study Site - Birmingham
- Regeneron Study Site - Mobile
Colorado
- Regeneron Study Site 1 - Aurora
- Regeneron Study Site 2 - Aurora
- Regeneron Study Site - Colorado Springs
Florida
- Regeneron Study Site - Lake Worth
- Regeneron Study Site - Lake Worth
- Regeneron Study Site - Miami Springs
Georgia
- Regeneron Study Site - Covington
Indiana
- Regeneron Study Site - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,176 participants |
| Start Date | 2016-11-02 |
| Est. Completion | 2020-03-05 |
| Phase | Phase 4 |
What the finished NCT02957682 record still lists
NCT02957682 is an interventional study that assigns participants to a tested intervention. Its 2,176 participants enrollment target places it among the larger protocols in the corpus, above the 782-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (178% higher).
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02957682 names 20 study sites across 7 states, led by California, Illinois, Alabama.
Frequently Asked Questions
What is clinical trial NCT02957682 about?
NCT02957682 is a clinical study titled "Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo". The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.
What is the current status of trial NCT02957682?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,176 participants. The study started on 2016-11-02. Estimated completion is 2020-03-05.
What conditions does trial NCT02957682 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT02957682?
The interventions under investigation include: Placebo (DRUG), Praluent (Alirocumab) (DRUG).
Who is sponsoring clinical trial NCT02957682?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02957682 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02957682's enrollment target sits among peer trials
2,176 5th of 62 higher than 58 of 62 other Hypercholesterolemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypercholesterolemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol
COMPLETED · Phase 4
-
Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol
COMPLETED · Phase 4
-
A Study Comparing CoQ10 Levels While Taking 3 Different Statins
COMPLETED · Phase 4
-
Cholesterol and Pharmacogenetic Study
COMPLETED · Phase 4
-
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
COMPLETED · Phase 4
-
Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05917652 · 2,183 participants
The Actuate-CBC Study
- NCT05742178 · 2,160 participants · NA
NYC Cancer Outreach Network in Neighborhoods for Equity and Community Translation
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI